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According to the Institute of Medicine in Washington, DC,
USA, preventable adverse events in the United States,
including nosocomial infections, are responsible for 44
000–98 000 deaths annually and represent a cost of
US$17–29 billion [1]. Among them, nosocomial infections
now concern 5–15% of hospitalized patients and can lead
to complications in 25–50% of those admitted to intensive
care units (ICUs) [2]. Pneumonia related to mechanical
ventilation, intra-abdominal infections following trauma or
surgery, and bacteremias or sepsis related to intravascular
devices account for more than 80% of these [3,4].
In the United States, it is estimated that up to
150 million intravascular devices are inserted into
hospitalized patients, and that 200 000–400 000
nosocomial bloodstream infections (BSIs) may occur each
year [3]. The National Nosocomial Infection Surveillance
(NNIS) system reported that most of these infections are
related to intravascular access, with rates substantially
higher among patients with central venous catheters
(CVCs) than among those with peripheral lines [3,4].
Overall, a central line is reported to be present in 50% of
ICU patients, and micro-organisms eventually colonize
25% of these lines [5–7]. Rates of infections range
between 2.8 and 12.8 episodes per 1000 catheter-days
and may have a significant impact on patient morbidity
and hospital costs in ICUs [4,8].
However, a large proportion of catheter-related
infections (CRIs) are preventable [9]. The newly
developed catheters coated with antiseptic(s) or
antibiotic(s) may represent a major advance in prevention
[7,10]. Moreover, recent data strongly suggest that a
global preventive strategy and/or educational programs
including a careful control of all factors associated with
CRIs may also be very effective [11,12].
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Catheter-related infection remains a leading cause of nosocomial infections, particularly in intensive care
units. It includes colonization of the device, skin exit-site infection, and device- or catheter-related
bloodstream infection. The last-mentioned represents the most frequent life-threatening associated
complication of central venous catheter (CVC) use and is associated with significant patient morbidity,
mortality, and extra hospital costs. The incidence of catheter-related bloodstream infection ranges from
2–14 episodes per 1000 catheter-days. On average, microbiologically documented device-related
bloodstream infections complicate 3–5 per 100 CVC uses; however, they represent merely the tip of the
iceberg, and most cases of clinical sepsis are nowadays considered to be catheter-related. This article will
briefly review the pathophysiology of these infections, highlighting the importance of the skin insertion
site and the intravenous line hub as principal sources of colonization. A short review of the principles of
therapy is also provided. The latest preventive approaches are presented in more detail, including the
possible benefit of recently developed impregnated catheters and the positive impact of educational
programs and/or a global preventive strategy based on strict application of preventive measures and on
careful control of all factors associated with catheter-related infection. This may help clinicians to
determine the eventual necessity to incorporate them in their own practice.
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Epidemiology and impact
CRIs include colonization of the device, skin exit-site
infection, and device-related BSI (Table 1). Accordingly,
the epidemiology varies considerably depending on the
type of device, its localization, and the purpose for which
it is used [13].
The most available data concern BSIs. These
represented 12% of all nosocomial infections reported in
10 038 patients from 1417 ICUs in the European
Prevalence of Infection in Intensive Care (EPIC) study
[13]. In a review of 30 prospective studies, Hampton and
Sherertz [14] reported the risk of CRI per day of
catheterization to be 1.3%, 1.9%, and 3.3%,
respectively, for venous peripheral, arterial, and venous
central lines. Data extracted from recent studies indicate
that the microbiologically documented catheter-related
bloodstream infection (CR-BSI) rate with all CVCs
averages 5% [5–7,15]. (Table 2). In addition, incidence-
density CVC-BSI rates allow comparisons between
different types of ICUs (Table 3).
Case-control studies have attempted to estimate the
impact of CRIs (Table 4). In a study of nosocomial BSI in
critically ill patients [8], significantly different mortality
rates were observed between patients with BSIs
acquired in a surgical ICU (50%) and closely-matched
controls (15%), corresponding to an attributable
mortality of 35% (95% CI 25–45). In the subgroup of
patients with CR-BSIs, the attributable mortality was
25%, with additional ICU stay and extra costs of 6.5
days and US$28 690, respectively [16]. In two recent
studies, DiGiovine et al. [17] and Rello et al. [18]
reported no attributable mortality (crude mortality 35%
vs. 31%, and 22% vs. 35%, respectively) but
significant increases in both length of stay (10 and 20
days, respectively) and in costs (US$16 000 and
US$4000 per episode, respectively). Overmatching
may, however, have played a role in these studies, with
possible undervaluation of estimates. Thus, assessing
the precise impact of CRI and CR-BSI is now crucial.
However, it will be necessary to control not only for the
severity of disease, but also for the type and duration of
catheter use and care, as well as for other major
confounding factors of outcome. 
Diagnosis and microbiology
As local signs may be completely absent, clinical
diagnosis of CVC-related infection may be difficult.
In addition, thrombophlebitis may be of non-
infectious origin, making these signs neither sensitive
nor specific.
Table 1. Definitions of catheter-related infections.
Type of condition Definitions
Catheter colonization In the absence of clinical signs of infection at the skin insertion site:
• Quantitative culture — <100 colony-forming units (CFUs) (Brun-Buisson)
• Quantitative culture — <103 CFUs (vortex)
• Semi-quantitative culture — <15 CFUs (roll-plate technique)
Exit-site infection At the insertion skin site of any vascular access: 
• Microbiologically documented — a positive (semi-) quantitative catheter culture in the presence of clinical signs of
infection (erythema, tenderness, induration, or purulence)
• Clinically documented — a clinical infection (erythema, tenderness, induration, or purulence)
Bloodstream infection • Primary bloodstream infection — refers to a bacteremia (or fungemia) for which there is no documented distal
source, and includes those resulting from an intravenous or arterial line infection
• Clinical sepsis — one of the following clinical signs or symptoms with no other recognized cause:
- fever (>38°C)
- hypotension (systolic blood pressure ≤90 mmHg)
- oliguria (>20 ml/h)
and all of the following: 
- blood culture not performed or no organism detected in blood
- no apparent infection at another site
- clinical response to appropriate empirical antimicrobial therapy
after vascular access removal and/or change
Catheter-related • Isolation of the same organism (i.e. identical species, antibiogram) from a quantitative culture of the distal
bloodstream infection catheter segment and from the blood of a patient with clinical symptoms of sepsis and no other apparent source of
infection
• In the absence of catheter culture, defervescence after removal of an implicated catheter from a patient with primary
bloodstream infection is considered as indirect evidence of catheter-related bloodstream infection 
Adapted from [61].
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Various methods for culturing the insertion site,
the catheter, and the blood have been described,
and a choice must be made according to preferred
sensitivity and specificity, both varying between 78%
and 95% [19] (Table 5).
Most micro-organisms implicated in CRIs arise from the
skin flora (Table 6). Gram-positive cocci are responsible
for at least two-thirds of infections. Coagulase-negative
staphylococci are the leading bacteria cultured from
catheters, but enterococci are not uncommon [7,15,20].
Table 2. Colonization and catheter-related bloodstream infection rates in selected ICU series with impregnated and
non-impregnated central venous lines.
Type of catheter Number in Catheter Catheter-related bloodstream
Author [ref] study colonization infections number (%)
number (%)
Non-impregnated
Bach et al. [62] * 117 36 (30.8) 3 (2.6)
Hannan et al. [63] ** 177 71 (40.1) 8 (4.5)
Heard et al. [15] *** 157 82 (52.2) 6 (3.8)
Loo et al. [64] † 81 25 (30.9) 3 (3.7)
Maki et al. [5] †† 195 47 (24.1) 9 (4.6)
Marik et al. [65] ††† 39 11 (28.2) 2 (5.1)
Raad et al. [6] ‡ 136 32 (23.5) 7 (5.1)
Tennenberg et al. [20] ‡‡ 145 32 (22.1) 9 (6.6)
van Heerden [66] ‡‡‡ 26 10 (38.5) 0 -
Silver-sulfadiazine/chlorhexidine impregnated 
Bach et al. [62] * 116 21 (18.1) 0 -
Hannan et al. [63] ** 174 47 (27.0) 3 (1.7)
Heard et al. [15] *** 151 60 (39.7) 5 (3.3)
Loo et al. [64] † 77 12 (15.6) 3 (3.9)
Maki et al. [5] †† 208 28 (13.5) 2 (1.0)
Marik et al. [65] ††† 36 7 (19.4) 1 (2.8)
Tennenberg et al. [20] ‡‡ 137 8 (5.8) 5 (3.7)
van Heerden [66] ‡‡‡ 28 4 (14.3) 0 -
Darouiche [7] § 382 87 (22.8) 13 (3.4)
Minocyclin/rifampin impregnated 
Marik et al. [65] ** 38 4 (10.5) 0 -
Raad et al. [6] ‡ 130 11 (8.5) 0 -
Darouiche et al. [7] § 356 28 (7.9) 1 (0.3)
* Quantitative level of bacterial colonization 52±17 vs. 256±86 colony-forming units (CFUs) for silver-sulfadiazine/chlorhexidine-impregnated
as compared with non-impregnated catheters, respectively; p<0.05. No significant differences for catheter-related bloodstream infections.
** Semi-quantitative analysis of bacterial counts for colonization of silver-sulfadiazine/chlorhexidine-impregnated as compared with non-
impregnated catheters; p<0.01. No significant differences for catheter-related bloodstream infections.
*** Odds ratio for colonization only: 0.59 (95% CI 0.34–0.97) for silver-sulfadiazine/chlorhexidine-impregnated as compared with non-
impregnated catheters, respectively; p=0.04.
† Catheter-tip positive cultures for silver-sulfadiazine/chlorhexidine-impregnated as compared with non-impregnated catheters; p<0.05. No
significant differences for catheter-related bloodstream infections.
†† Odds ratio for colonization: 0.56 (95% CI 0.36–0.89) for silver-sulfadiazine/chlorhexidine-impregnated as compared with non-impregnated
catheters, respectively; p<0.005. Odds ratio for catheter-related bloodstream infection: 0.21 (95% CI 0.03–0.95) for silver-
sulfadiazine/chlorhexidine-impregnated as compared with non-impregnated catheters, respectively; p=0.03.
††† Semi-quantitative cultures of distal segment for minocyclin/rifampin-coated as compared with non-impregnated catheters; p=0.5. No
significant differences for catheter-related bloodstream infections. 
‡ Odds ratio for colonization: 0.25 (95% CI 0.12–0.53) for minocyclin/rifampin-coated as compared with non-impregnated catheters,
respectively; p<0.001. The rates of catheter-related bloodstream infection per 1000 catheter-days were 7.34 for non-impregnated and 0 for
impregnated catheters (p<0.01; binomial exact test).
‡‡ Risk reduction for colonization only: 43% for silver-sulfadiazine/chlorhexidine-impregnated as compared with non-impregnated catheters,
respectively; p<0.001.
‡‡‡ Semi-quantitative cultures of distal segment for silver-sulfadiazine/chlorhexidine-impregnated as compared with non-impregnated catheters,
respectively, p<0.05. No significant differences for catheter-related bloodstream infections.
§ Odds ratio for colonization: 0.35 (95% CI 0.23–0.52) for minocyclin/rifampin-impregnated as compared with silver-sulfadiazine/chlorhexidine-
impregnated catheters, respectively; p<0.001. Odds ratio for catheter-related bloodstream infection: 0.08 (95% CI 0.01–0.63) for
minocyclin/rifampin-impregnated as compared with silver-sulfadiazine/chlorhexidine-impregnated catheters, respectively; p<0.0001.
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Staphylococcus aureus (S. aureus) is responsible for
5–15% of the infections and is associated with a higher
rate of complications [21]. Gram-negative bacilli may
colonize invasive monitoring pressure systems, orotracheal
cavities, and complicated remote infections, particularly in
critically ill patients [22]. Candida species have emerged
as an important source of CRIs, and account for a high
proportion of the dramatic increase in the rate of
candidemia over the last decade [3]. 
Pathogenesis and risk factors
Four distinct pathways may be identified in the
development of CRI (Fig. 1) [3]. External surface
pathway infection may start with the colonization of the
insertion site by micro-organisms that may move by
capillary action through the transcutaneous part of the
dermal tunnel surrounding the catheter. Internal surface
pathway infection may occur by colonization of the hub
and intraluminal surface of the catheter [23]. Host
glycoproteins, such as fibrinogen, fibronectin, collagen,
and laminin, adsorbed on the surface of intravenous
devices, form a layer that enhances bacterial adherence
— in particular, S. aureus and coagulase-negative
staphylococci — to foreign material. In addition, some
strains produce a mucoid exopolymeric substance
(slime), conferring them some protection against
antimicrobials and interfering with neutrophil function
[24]. Skin colonization is a strong predictor of CRIs
[22,25]. Frequent opening of the hub is now viewed as
an important source of colonization [5,7,26]. Additional
risk factors predisposing to colonization and infection are
catheter material, line insertion, localization, and type of
care. Hematogeneous seeding of the catheter during BSI
of any origin represents a third pathway of CRIs [9].
Finally, contamination of the fluids or drugs
intravenously administered constitutes another pathway
of CRIs, sometimes responsible for outbreaks [3].
Treatment
Removal of a catheter suspected to be infected is
strongly recommended. Catheter retention may result in
a several-fold higher risk for recurrence of BSI. Removal
is mandatory in severe or complicated infections such as
shock, persistent fever or bacteremia, or with certain
micro-organisms (S. aureus, Gram-negative bacilli,
Candida spp) [3,27].
However, systematic removal of a CVC with insertion
at a new site was proven to be unnecessary in 75% to
90% of cases [9,28,29]. This may, in part, explain why
catheter exchange over a guidewire has been generalized
in most ICUs. This technique may increase the likelihood
of infection of the new catheter, but reduces the rate of
complications associated with CVC placement in a new
site, which may be technically difficult in some severely ill
patients requiring multiple vascular accesses [28].
Randomized prospective studies have failed to detect any
preventive benefit associated with guidewire exchange
compared with insertion at a new site [29]. However, it is
the opinion of many experts that this technique can be
performed in critically ill patients with limited sites for
new vascular access, but meticulous aseptic technique is
imperative [9]. Practically, our opinion is that guidewire
exchange together with systematic (semi-) quantitative
culture of the catheter tip is mandatory in any case of
sepsis without clinical evidence of another source of
infection [12]. Removal of the exchanged catheter
followed by further insertion at a new site is then
absolutely indicated in the presence of a positive culture
of the removed material (Fig. 2). The possible benefit of
concomitant antibiotic administration at time of catheter
replacement needs to be investigated.
Several studies have reported successful conservative
treatment of CRIs, particularly bacteremia due to
coagulase-negative staphylococci, without removal of
the catheter. The technique of antibiotic-lock may be
particularly helpful in avoiding difficult vascular access
replacement in patients with implanted or permanent
devices [30]. 
Although some authors recommend no treatment
once the catheter is removed, many authorities prefer to
Figure 1. Colonization pathways involved in
intravenous-catheter-related infection. External and
internal catheter surface colonization pathways involve
colonization of the skin insertion site and hub,
respectively. Additional pathways include microbial
contamination of the infusate (so-called intrinsic
contamination), and hematogeneous seeding.
Infusate Internal
External
Hematogenous
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treat with an appropriate antibiotic course (5–7 days for
uncomplicated coagulase-negative staphylococci). In
patients with CRIs caused by S. aureus, treatment
duration should be 10–14 days, although recent data
have suggested that a transesophageal echocardiogram
may help to identify vegetation(s) that requires a specific
management in a significant proportion of patients [31]. 
Relapse, continuous fever, or bacteremia despite removal
of the catheter involves an active search for complications
such as another line-associated infection, metastatic
abscess, septic thrombophlebitis, or endocarditis. Following
treatment completion, careful follow-up is required owing
to the frequent occurrence of late complications [3,25].
Prevention
More than 50% of patients admitted to ICUs are, at the
time of admission, already colonized with the organism
responsible for subsequent infection, although some of
them will acquire it from the environment [32].
Nevertheless, the prevention of CRIs relies on a careful
control of all the factors associated with the colonization
of vascular accesses by micro-organisms. Evidence-based
guidelines and preventive measures were published by
the Hospital Infections Control Practices Advisory
Committee in 1996 [9]. This topic was also recently
extensively reviewed elsewhere [33,34].
Despite these recommendations, the rates of CRIs did
not significantly decrease until the development of
antibiotic/antiseptic-coated catheters (Table 2), and,
more recently, by the application of educational
programs (Table 7). 
Antibiotic- and antiseptic-coated catheters
Intraluminal antibiotic locks or flushes with vancomycin
have been reported to reduce the rate of CRIs, but only
few studies have been conducted in ICU patients [35].
Moreover, the use of antibiotics for this purpose could
lead to the emergence of vancomycin-resistant Gram-
Figure 2. Approach to a patient with clinical sepsis suspected to be related to a vascular access site.
*Cut-off values vary with the technique used for the diagnosis [22,83,84] (Table 5).
CFU: colony-forming units
Vascular access to be
removed and inserted at a new site
Vascular access inserted through
the guidewire can be kept
Positive culture*
  15 CFU (roll-plate)
  102 CFU (quantitative)
  103 CFU (quantitative)
Positive culture*
<15 CFU (roll-plate)
<102 CFU (quantitative)
<103 CFU (quantitative)
(Semi)quantitative culture of the distal segment
Remove the vascular access
Guidewire exchange is not allowed
Remove the vascular access
through guidewire exchange
Remove the
vascular access
Access not neededAccess needed
Pus at the skin exit-site of the vascular access?
Clinical signs of sepsis without infection at another body site
NoYes
≥
≥
≥
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positives, which must be avoided because glycopeptide
antibiotics are the only drugs available for the treatment
of infections due to methicillin-resistant staphylococci
and penicillin-resistant enterococci [9].
Two prospective, randomized clinical studies [5,6]
suggested that the use of CVCs impregnated with either
chlorhexidine and silver sulfadiazine or minocycline and
rifampin was associated with a significant reduction of
microbiologically documented CRIs — 44% and 79%,
respectively. These results were confirmed by another
study [15] and a recently published meta-analysis [10]. In
addition, a cost-effectiveness analysis based on the
results of this meta-analysis suggested that the use
of chlorhexidine/sulfadiazine-impregnated catheters
decreased the absolute incidence of CR-BSI ranged from
1.2% to 3.4%, corresponding to a cost saving of US$68
to US$391 per catheter used [36].
A direct comparison between these new materials was
subsequently undertaken in a multicenter study [7]. The
minocycline/rifampin-impregnated catheter was reported
to be associated with significantly lower colonization
(relative risk [RR] 0.35; 95% CI 0.24–0.55) and CR-BSIs
(RR 0.08; 95% CI 0.01–0.63). The authors argued that
this difference may be due, in part, to the absence of
chlorhexidine and silver sulfadiazine in the intraluminal
surface. This is consistent with another study in which the
silver/chlorhexidine catheters were not associated with a
reduction of the CRI rate [37]. Furthermore, data from a
study that evaluated colonization and residual ex vivo
antimicrobial activity after removal of 113 CVCs that were
no longer required, strongly favors this hypothesis [38].
However, the time of catheterization may have played a
role. Impregnated catheters failed to prevent CRIs in
neutropenic cancer patients with a mean catheterization
time of 20 days as compared with 6, 7, and 8.3 days for
the previously mentioned studies [5–7,37]. A meta-
analysis confirmed that the potential benefit of these
devices may be lost after 7 to 10 days [39].
Educational programs
Sherertz et al. [11] recently reported that an educational
program for physicians-in-training can also decrease the
risk for CRIs. A 1-day course on infection control
practices and on procedures of vascular access insertion
was shown to reduce the infection rate by 27%, from
3.3 to 2.4 per 1000 CVC-days (Table 3).
A recent study evaluated the impact of a global strategy
targeted at the reduction of CRIs in 3154 critically ill
patients consecutively admitted to a medical ICU [12].
Following the introduction of this educational program,
the incidence-density of exit-site catheter infection
Figure 3. Incidence of nosocomial infections before and
after the implementation of a global strategy targeted
at vascular access care. A: effect on all nosocomial
infections (p<0.0001). B: effect on respiratory
tract infections (p=0.75); on skin or mucous
membranes (p=0.02); on urinary tract infections
(p=1.0); on skin exit-site infections (p<0.0001).
C: effect on bloodstream infections expressed as
episodes per 1000 catheter-days (p<0.0001) due to the
effect both on primary bloodstream infections
(p<0.001) and on clinical sepsis (p<0.001).
Adapted from [12].
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decreased by 64%, and that of BSI by 67%. Although the
overall exposure to the CVC did not significantly differ
between the control and the intervention periods (median
duration, 4.1 vs. 3.9 days; p=0.94), the incidence-density
of BSI markedly decreased from 22.9 to 6.2 episodes per
1000 CVC-days, owing to a reduced incidence of both
microbiologically documented infection (from 6.6 to
2.3 episodes per 1000 CVC-days) and clinical sepsis
Table 3. CVC-related nosocomial infection rates in selected ICUs. 
Author [ref] Type of Period Number Bloodstream infections
ICU of units per 1000 CVC-days
NNIS [4] Medical 1997–1999 135 5.3 (3.6–7.1) *
Coronary 1997–1999 112 4.0 (1.7–6.3) *
Surgical 1997–1999 157 5.1 (2.6–7.0) *
Pediatric 1997–1999 73 6.9 (4.1–9.3) *
Eggimann et al. [12] Medical 1997 1 2.3 ** -
Medical 1996 1 6.6 -
Sherertz et al. [11] Mixed 1997 6 2.4 *** -
Mixed 1996 6 3.3 -
Legras et al. [67] Mixed 1995 5 4.8 -
Singh-Naz et al. [68] Pediatric 1993 1 8.9 -
Pediatric 1995 1 16.8 -
Gastmeier et al. [69] Neonatology 1997 1 12.5 -
Finkelstein et al. [70] Mixed 1998 1 12.0 -
Simon et al. [71] Pediatric 1998 1 10.7 -
Weber et al. [72] Burn 1990–1991 1 4.9 -
Dettenkoffer et al. [73]  Neurosurgical 1997–1998 1 0.9 -
* 50th percentile (25th–75th).
** After the implementation of a global strategy targeted at the reduction of catheter-related infections.
*** After the implementation of an educational program targeted at the reduction of catheter-related infections.
Table 4. Impact of nosocomial bloodstream infections (BSIs) in selected groups of patients. 
Author [ref] Year of Study Number Mortality Crude Attributable Attributable Costs
publication period of cases Type of BSI (%) (%) LOS *(days) (US$)
Hospital-wide
Rose et al. [74] 1977 40 Nosocomial ** 38.0 28 11.0 4400
Spengler [75] 1978 1972–1974 99 Nosocomial ** 32.9 28 9.0 5800
Wey et al. [76] 1988 1983–1986 88 Candidemia 57.0 38
Martin et al. [77] 1989 1984–1987 118 Nosocomial *** 30.5 17 8.5
ICUs
Forgacs et al. [78] 1986 1970–1985 468 Nosocomial ** 60.4 47†
Smith et al. [79] 1991 1986–1989 34 Nosocomial ** 82.4 30
Rello et al. [80] 1994 1990–1992 111 Nosocomial ** 31.5 65†
Pittet et al. [8] 1994 1988–1990 86 Nosocomial ** 50.0 35 24.0 40 000
Pittet et al. [16] 1994 1988–1990 20 Catheter-related 45.0 25 6.5 29 000
Wisplinghoff et al. [66] 1999 1990–1992 29 Nosocomial †† 31.0 16 20.0
Soufir et al. [81] 1999 1990–1995 38 Catheter-related 50.0 29
DiGiovine et al. [17] 1999 1994–1996 68 Nosocomial ††† 35.3 4§ 10.0 35 000
Rello et al. [18] 2000 1992–1999 49 Catheter-related 22.4 13§ 20.0 4000
* LOS: length of stay.
** Includes both primary and secondary bloodstream infections.
*** Primary coagulase-negative staphylococci (CNS) bacteremia only.
† Attributable mortality was not determined in a matched-control study, but by simple comparison with the crude mortality of all patients who
did not develop a bloodstream infection.
†† Acinetobacter baumannii nosocomial bloodstream infections only.
††† Includes primary bloodstream infections only.
§ Differences are non-significant.
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(from 16.3 to 3.9 episodes per 1000 CVC-days) (Fig. 3).
Overall, the incidence-density of nosocomial infections
was reduced by 35% (from 52.4 to 34.0 episodes per
1000 patient-days), corresponding to the prevention of
more than 75 nosocomial infections over an 8-month
period, including at least 30 primary BSIs and 25 vascular
access-related infections. It was estimated that this would
also correspond to the annual salary of three full-time
infection control nurses.
The impact in terms of reduction of nosocomial
infections in these two studies was largely superior to that
expected with the use of antimicrobial/antisepsis-coated
catheters [10,36]. Thus, behavioral changes may have
played a key role in the success of these educational
programs, which were based on a multimodal and
multidisciplinary approach including communication and
education tools, active participation and positive feedback,
and systematic involvement of the leaders [40,41].
Specific guidelines 
Specific guidelines included in the global strategy
implemented through an educational program targeted
at vascular access care are presented in Table 7. Most of
them are supported by clinical studies with limited
strength of evidence. In the absence of randomized
double-blind trials, some of them are discussed in the
following paragraphs. 
The program consisted of slide-show-based
educational sessions and bedside training of all the staff
including nurses (Figs. 4–6). 
Hand-hygiene measures
As is the case for other nosocomial infections, prevention
is mostly based on a strict application of the concepts of
standard precautions [42]. A strict adherence to hand-
hygiene measures (hand washing and/or hand
Table 5. Sensitivity and specificity of cultures performed for the diagnosis of catheter-related infection.
Type of culture Sensitivity Specificity
Methodology (%) (%)
Rapid diagnosis
Gram’s stain and acridine-orange leukocyte cytospin test * 96 92
Direct microscopic examination of blood drawn through the suspected vascular access, and processed to be
stained with acridine orange and Gram’s stain [82]
Catheter culture
Qualitative catheter segment culture: 95 75
Colony-forming units (CFUs) are not counted
Semi-quantitative catheter segment culture: 85 85
A 2-inch distal portion of the catheter is rolled four times over the surface of a sheep-blood agar plate and
incubated for 48 h. Cut-off value >15 CFUs per segment (roll-plate technique) [22]
Quantitative catheter segment culture: 94 92
Vortexing, sonicating, flushing, and vortexing the catheter with serial dilutions of the specimens obtained. 
Cut-off value >102–103 CFUs per segment [83,84]
Blood cultures
Standard blood cultures: 91 86
Two sets of blood cultures (two bottles each) with at least one drawn percutaneously
Quantitative blood cultures: 79 94
Differential quantitative culture of two sets of blood cultures, one drawn percutaneously and the other
through the suspected vascular access
Differential-time blood cultures: 91 94
Differential time to positivity of two sets of blood cultures drawn simultaneously, percutaneousely and from
the suspected vascular access [85]
Adapted from [19] and [82–85].
* Sensitivity and specificity were reported to be 87% and 94%, respectively, in a previous experience with acridine-orange leukocyte cytospin [86].
Table 6. Micro-organisms associated with device-
related bloodstream infections.
Proportion (%)
Common micro-organisms
Coagulase-negative staphylococci 60–70
S. aureus 5–15
Candida spp 5–10
Enterobacteriaceae 5–10
Less common micro-organisms
Enterococci 2–4
Methicillin-resistant S. aureus 2–4
Commonly responsible for outbreaks
Burkholderia spp <1
Malassezia spp <1
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disinfection) and aseptic techniques for any patient
and/or device care is the key requirement of these
precautions [43].
However, low-level compliance with hand washing has
been repeatedly reported, particularly in ICUs [44,45].
Experience with alcohol-based handrubs has suggested
that hand disinfection reduces hand contamination as
compared with that achieved with hand washing, and
may spare precious time in the ICU, where, in theory,
almost two-thirds of work-time of the staff could be
required for optimal adherence to infection control
guidelines [46,47]. In a French medical ICU, the increase
in compliance to hand-hygiene measures — from 42%
to 61% — was essentially attributed to the availability of
an alcohol solution for handrubs [48]. However, these
effects were not sustained, and compliance decreased
again over the next few months. A recent hospital-wide
campaign promoting an elementary bedside hand-
disinfection technique resulted in a sustained
improvement in compliance with hand hygiene — from
48% to 66% over a 4-year period [49]. During the same
period, the prevalence of overall nosocomial infections
decreased significantly, from 17% to 9%.
Technique of catheter insertion
Skin preparation should include the cutting, rather than the
shaving, of hair [11,12]. Maximal sterile barrier precautions
during insertion — including the use not only of large and
fenestrated drapes and sterile gloves, but also of gown,
cap, mask, and a large drape — can minimize catheter
colonization and subsequent CRIs [50]. Rigorous cleansing
and disinfection of the insertion site is regarded as a key
point. Solutions of povidone-iodine (10%) and alcohol
(70%) are effective, but aqueous chlorhexidine (2%) has
been shown to be superior in preventing CVC colonization
[51]. An alcohol-based preparation of chlorhexidine
gluconate (0.5%) may combine the advantages of a
greater antimicrobial spectrum, and a very rapid killing of
skin micro-organisms and drying time, at low cost.
Antimicrobial ointments have been used to prevent
catheter colonization, but they favor colonization with
resistant organisms and are no longer recommended [9]. 
Table 7. Guidelines for insertion and handling of vascular accesses in intensive care unit patients to prevent the
development of catheter-related infections
Hygiene Hand disinfection Strongly emphasized for any care (http://www.hopisafe.ch)
Hand washing Restricted for dirty hand, followed by hand disinfection
Material Preparation Material disposed according to detailed listing to avoid interruptions during the insertion *
Patient Installation Patient and devices are disposed in order to manage sufficient access to the insertion site for the
operator
Insertion Skin preparation Hair cutting instead of shaving
Antisepsis Alcohol-based (60–70%) solution of chlorhexidine gluconate 0.5%
Technique Maximal barrier precautions: sterile gown and gloves, cap, surgical mask, large sterile drapes 
Site Promotion of subclavian (CVC) and wrist vein (short lines) sites
Fixation Promotion of simple node at the exit site, without special fixing
device (Fig. 4)
Dressing Transparent dress Occlusive devices without gauze not allowed 
Dry gauz: Occlusion with porous adhesive band imposed (Fig. 5)
Handling General measure New caps after any opening of the hubs
Blood sampling On antiseptic-impregnated pads 
Drug infusions Idem, new temporary pipe for each administration 
Cardiac output: Closed system only, without opening of the circuit
Replacement 72 h intervals For dress, sets, pipes, and devices
24 h intervals For lipid or blood products lines
Removal In general Peripheral lines after 72 h
Central lines as clinically indicated
Prompt removal if vascular accesses not absolutely necessary
Special conditions Guidewire exchange systematically performed for any unexplained clinical sepsis ** (see Fig. 6)
Adapted from [9] and [12].
* Precise listing of the material needed, as well as detailed description of the insertion process, must be given to all the staff of the unit
including physicians, nurses, and nursing assistants.
** Clinical sepsis was defined as the one of the following clinical signs or symptoms with no other recognized cause: fever (>38°C), hypotension
(systolic blood pressure ≤90 mmHg), or oliguria ( >20 ml/h), and all of the following: blood culture not performed or no organism/antigen
detected in blood, no apparent infection at another site, physician institutes appropriate antimicrobial therapy for sepsis [61].
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Site of insertion
Growing evidence has suggested repeatedly that central
lines inserted in the jugular site are more likely to be
colonized than those inserted by the subclavian route
[7,15,18]. This could be related to factors favoring skin
colonization, such as proximity of oropharyngeal
secretions, higher skin temperature, and difficulties in
immobilizing the catheter and maintaining an optimal
dressing, particularly in men [7]. Although the reported
rate of infection with CVCs inserted through the
femoral vein has remained stable since the beginning of
the 1990s, and despite potentially less severe
complications related to their insertion, they may be
associated with a higher rate of deep venous
thrombosis, and insufficient data are presently available
to recommend their use [52].
The use of tunneled short-term CVCs has been
reported to be associated with a decreased rate of CRI,
but a recent meta-analysis of randomized controlled
trials concluded that it might be the case only for
those inserted in the jugular site [53]. An accompanying
editorial highlighted the fact that blood-draws through
the catheters were not allowed in the study [54],
and it was this that determined the positive result of
this analysis [55]. The same comment has to be made
about the recent large randomized controlled study
from the same group [56], in which the authors
reported that a catheter-related sepsis occurred in 5 of
168 patients who received a femoral tunneled CVC as
compared with 15 of 168 who received a non-tunneled
CVC (RR 0.25; 95% CI 0.09–0.72) [56]. The proportion
of CVCs used for blood draw is generally not specified
in most studies, and many institutions favor arterial
lines for this purpose.
Careful fixation of the catheter at the skin
exit-site might avoid complications such as leakage
of the fixing device and movements through the
intradermic portion (Fig. 4).
Figure 4. Promotion of a simple fixation system included in the guidelines (part of the slide-show session included in
the educational program) [12]. A: after the insertion of a multiple-lumen central venous catheter in the subclavian
position, a wire is passed around the emergence of the catheter and loosely tied. B: the wire is laced around the
catheter at its emergence. C: the wire is firmly tied up in order to avoid eventual further slide-up. D: all bloody marks
are scrupulously removed, and the exit site is meticulously disinfected before dressing.
A B
C D
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Dressing
Catheter-site dressing has generated considerable
literature for decades, yielding debates and
contradictory findings. Semi-permeable transparent
dressings are widely used. They are simple to place,
allow continuous observation of the skin insertion site,
and reduce the risk of extrinsic contamination.
However, they promote moisture and bacterial
proliferation under the cover and have been associated
with higher CRI rates as compared with traditional
gauze dressings [57]. Therefore, the use of transparent
dressings cannot be recommended in critically ill
patients. In addition, a small dressing is easier to secure
(Fig. 5). The precise duration a dressing can be safely
left on a central line is unknown, but it should be
systematically renewed every 48–72 h, if an earlier
change is not clinically indicated.
Catheter handling
Recommendations for daily replacement of tubing were
made in the 1970s, after several epidemics of BSIs related
to intrinsic contamination of intravenous fluid, and have
been amply documented [3]. Currently, except for blood
products and lipid emulsions, administration sets can be
safely replaced every 72 h only [9]. Infusion therapy teams
have been reported to decrease CRI rates, but a recent
study suggested that appropriately trained personnel
might be as effective [58].
Figure 5. Promotion of a small dry gauze-based
dressing included in the guidelines (part of the slide-
show session included in the educational program)
[12]: The catheter hub is taken away from the neck
and dry gauze is disposed over the catheter at its skin
exit-site. The dress is ended by apposition of a porous
adhesive band, which may easily be taken off after
use of an alcohol-based (60–70%) solution of
chlorhexidine gluconate 0.5%.
Figure 6. Promotion of a guidewire-exchange
technique applied to the introducer used in the unit,
included in the guidelines (part of the slide-show
session included in the educational program) [12].
A: after meticulous disinfection of the skin exit-site,
large sterile drapes are installed. B: after introduction
of the guidewire by the front port, the lateral line of
the introducer is cut over a clip. C: in order to avoid
direct contact with a potentially contaminated device,
the introducer is removed over the guidewire by
traction on the clip over a pad impregnated with a
disinfectant solution. The new catheter will be
introduced through the guidewire.
A
B
C
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A four-fold decrease of CRI rate was reported with
the use of an antiseptic hub model as compared to
standard model, in a prospective survey of 151
subclavian CVCs inserted for a mean duration of
2 weeks [59]. This was associated with a significant
reduction of CR-BSIs attributed to the hub (1% vs.
11%) and with the fact that a smaller proportion of
catheters were removed for clinical suspicion of CRI
(19% vs. 42%). Such preliminary results call for further
randomized trials. 
Catheter replacement and/or exchange?
The duration of catheterization has been linked to the
risk of CRIs, particularly after 7 days [7,15,60], but
systematic routine replacement of central lines has failed
to prove its efficacy in decreasing the risk [28]. Catheter
exchange over guidewire is discussed in the paragraph
on treatment (Fig. 6). 
Conclusion
Catheter-related infections should no longer be
considered as an indirect tribute to sophisticated care or
regarded as a fatality, but must become one of the
priority targets of a multidisciplinary approach
emphasizing quality-of-care improvement.
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